* Announced results from phase 2a SLE-001 trial evaluating CC-220, co's investigational, oral immunomodulatory compound

* Most common adverse events in trial were nausea, diarrhea and maculopapular rash

* No opportunistic infections or other systemic infections were reported in any CC-220 dose groups in trial

* Serious adverse events were reported in two patients in two highest CC-220 doses combined and in two patients in placebo group Source text for Eikon: Further company coverage: